EU Medicines Watchdog Backs New Biosimilar for Cancer Treatment

Biocon has secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its Pertuzumab biosimilar. A biosimilar is the pharmaceutical world's equivalent of a painstaking replica: a biological medicine designed to match an existing brand-name drug in quality, safety, and effectiveness once original patent protections lapse. In this case, the drug targets specific types of cancer, offering healthcare systems a potentially lower-cost alternative to the original therapy.

Biological treatments represent some of the most expensive items on hospital receipts across Europe. Introducing biosimilars creates price competition that can significantly lower the bill for national healthcare services, stretching public health budgets further and widening patient access to high-cost oncology treatments.

While the scientific scrutiny happens at the EMA's headquarters in Amsterdam, the EU administrative machinery still requires a final nod from Brussels. The CHMP recommendation is the technical heavy lifting of drug evaluation; it provides the scientific foundation that the European Commission relies upon before converting expert consensus into a legally binding marketing authorization that covers all EU member states.

The CHMP's positive opinion will now be forwarded to the European Commission for a formal decision on marketing authorization, a step that typically follows within two months. Once approved, individual EU member states will handle local pricing and reimbursement decisions before the drug hits hospital pharmacies.